← Back to Calendar

atacicept

Vera Therapeutics · $VERA
Priority Review Breakthrough Therapy BLA
PDUFA Date
July 7, 2026
Time Remaining
85 days
Review Type
Priority (6 mo)
88%
Baseline PoA
BLA priority review approval rate
Based on FDA historical approval rates by submission type (2015–2025)
Dynamic PoA
Coming soon
xAI Sentiment

Live Company Data NGM

Updated just now · Data: FMP
Current Price
$45.04 +106.51%
+$23.23 today
Day: $40.50 – $47.00
Market Cap
N/A
Shares out: 71.71M
Float: 51.44M
52-Week Range
$18.76
$56.05
Current price is at 70% of 52-week range
Avg Volume
1.18M
Beta
1.17
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $VERA catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

IgA nephropathy (IgAN)

Key Notes

BLA submitted via Accelerated Approval Program. FDA granted Priority Review January 2026. PDUFA July 7, 2026. ORIGIN Phase 3 data: 46% reduction in proteinuria from baseline; 42% reduction vs placebo (p<0.0001) at week 36. Would be first B-cell modulator targeting both BAFF and APRIL for IgAN. Sub-$7B cap.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar